These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23912921)

  • 1. Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.
    Andrikopoulos GK; Fragoulakis V; Maniadakis N
    Hellenic J Cardiol; 2013; 54(4):289-300. PubMed ID: 23912921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.
    Kansal AR; Sorensen SV; Gani R; Robinson P; Pan F; Plumb JM; Cowie MR
    Heart; 2012 Apr; 98(7):573-8. PubMed ID: 22422743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    McKeage K
    Pharmacoeconomics; 2012 Sep; 30(9):841-55. PubMed ID: 22734683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
    Wouters H; Thijs V; Annemans L
    J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
    Chang CH; Yang YH; Chen JH; Lin LJ
    Thromb Res; 2014 May; 133(5):782-9. PubMed ID: 24642004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
    Faria R; Spackman E; Burch J; Corbacho B; Todd D; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2013 Jul; 31(7):551-62. PubMed ID: 23620211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.
    Marshall S; Fearon P; Dawson J; Quinn TJ
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):29-42. PubMed ID: 23402443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
    Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
    Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.